The active ingredients target a series of genes, including MAPK3, MAPK1, HSP90AA1, STAT3, PIK3R1, PIK3CA and AKT1, and can potentially regulate the PI3K/AKT, MAPK/ERK, Ras, cAMP and Rap1 signaling pathways to exert a neuroprotective role in patients with ischemic stroke, Qi deficiency and blood stasis syndrome. This evidence concerns the gene HSP90AA1 and ischemic stroke.